An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the activity and safety of telaprevir on Hepatitis C
Virus (HCV) Genotype 4, alone or in combination with standard therapy, that is,
pegylated-interferon-alfa-2a and ribavirin in treatment-naive (never been treated before with
antiretroviral therapy) participants.